Table 1.
Demographic features of patient subgroups by duration of symptoms and clinical follow-up
| Symptom duration ≤2 years
|
Symptom duration >2 years
|
|||
|---|---|---|---|---|
| ≤2 years of clinical follow-up | >2 years of clinical follow-up | ≤2 years of clinical follow-up | >2 years of clinical follow-up | |
| Idiopathic Parkinson’s disease | ||||
|
| ||||
| Number of patients | 9 | 21 | 8 | 58 |
| Sex (male, female) | 5, 4 | 15, 6 | 5, 3 | 41, 17 |
| Age at FDG-PET (years) | 60·4 (11·2) | 54·7 (10·1) | 59·3 (7·5) | 57·7 (9·4) |
| Symptom duration at FDG-PET (years) | 1·4 (0·4) | 1·5 (0·5) | 6·1 (3·3) | 8·3 (3·9) |
| Hoehn and Yahr stage | 1·8 (0·7) | 1·6 (0·6) | 2·5 (0·4) | 2·7 (0·8) |
| UPDRS | 14·1 (8·8) | 15·8 (12·3) | 26·7 (9·3) | 29·9 (12·3) |
| Clinical follow-up (years) | 1·2 (0·4) | 5·5 (2·1) | 1·4 (0·4) | 6·1 (2·6) |
|
| ||||
| Multiple system atrophy | ||||
|
| ||||
| Number of patients | 5 | 6 | 11 | 19 |
| Sex (male, female) | 2, 3 | 3, 3 | 5, 6 | 8, 11 |
| Age at FDG-PET (years) | 59·3 (8·7) | 59·1 (6·5) | 63·8 (9·8) | 60·6 (9·0) |
| Symptom duration at FDG-PET (years) | 1·8 (0·4) | 1·7 (0·5) | 4·0 (1·8) | 5·1 (1·9) |
| Hoehn and Yahr stage | 2·3 (0·6) | 2·6 (1·1) | 3·3 (1·0) | 3·9 (1·1) |
| UPDRS | 28·7 (8·7) | 27·2 (15·8) | 36·1 (17·3) | 37·6 (11·7) |
| Clinical follow-up (years) | 1·0 (0·5) | 6·0 (3·9) | 1·0 (0·2) | 4·2 (1·6) |
|
| ||||
| Progressive supranuclear palsy | ||||
|
| ||||
| Number of patients | 8 | 6 | 9 | 7 |
| Sex (male, female) | 4, 4 | 3, 3 | 4, 5 | 3, 4 |
| Age at FDG-PET (years) | 66·2 (4·8) | 66·6 (9·8) | 70·1 (6·6) | 74·5 (6·1) |
| Symptom duration at FDG-PET (years) | 2·0 (0·0) | 1·5 (0·5) | 4·6 (1·0) | 3·6 (0·8) |
| Hoehn and Yahr stage | 3·0 (0·0) | 2·8 (0·5) | 3·3 (0·5) | 3·5 (1·0) |
| UPDRS | 24·1 (11·8) | 20·8 (10·2) | 23·3 (14·2) | 32·8 (23·4) |
| Clinical follow-up (years) | 1·1 (0·5) | 3·2 (0·7) | 1·1 (0·5) | 2·7 (0·9) |
Values are mean (SD). UPDRS=Unified Parkinson’s disease rating scale, part III.